|
Gene: HDC |
Gene summary for HDC |
Gene summary. |
Gene information | Species | Human | Gene symbol | HDC | Gene ID | 3067 |
Gene name | histidine decarboxylase | |
Gene Alias | HDC | |
Cytomap | 15q21.2 | |
Gene Type | protein-coding | GO ID | GO:0001692 | UniProtAcc | P19113 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3067 | HDC | CA_HPV_1 | Human | Cervix | CC | 1.90e-14 | -4.60e-01 | 0.0264 |
3067 | HDC | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 1.66e-04 | 3.33e-02 | 0.0208 |
3067 | HDC | N_HPV_2 | Human | Cervix | N_HPV | 1.76e-02 | -3.56e-01 | -0.0131 |
3067 | HDC | CCI_1 | Human | Cervix | CC | 2.11e-03 | -5.60e-01 | 0.528 |
3067 | HDC | CCI_2 | Human | Cervix | CC | 5.80e-03 | -5.60e-01 | 0.5249 |
3067 | HDC | CCI_3 | Human | Cervix | CC | 3.56e-05 | -5.60e-01 | 0.516 |
3067 | HDC | CCII_1 | Human | Cervix | CC | 6.78e-08 | -5.60e-01 | 0.3249 |
3067 | HDC | Tumor | Human | Cervix | CC | 2.52e-20 | -5.60e-01 | 0.1241 |
3067 | HDC | sample1 | Human | Cervix | CC | 2.70e-06 | -5.60e-01 | 0.0959 |
3067 | HDC | sample3 | Human | Cervix | CC | 4.65e-21 | -5.60e-01 | 0.1387 |
3067 | HDC | H2 | Human | Cervix | HSIL_HPV | 1.62e-17 | -5.49e-01 | 0.0632 |
3067 | HDC | L1 | Human | Cervix | CC | 7.67e-09 | -5.60e-01 | 0.0802 |
3067 | HDC | T1 | Human | Cervix | CC | 8.70e-16 | -5.60e-01 | 0.0918 |
3067 | HDC | T2 | Human | Cervix | CC | 1.07e-02 | -5.60e-01 | 0.0709 |
3067 | HDC | T3 | Human | Cervix | CC | 3.12e-19 | -5.60e-01 | 0.1389 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Cervix | CC: Cervix cancer | |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005116824 | Oral cavity | EOLP | nuclear export | 47/2218 | 154/18723 | 4.45e-10 | 3.76e-08 | 47 |
GO:002261826 | Oral cavity | EOLP | ribonucleoprotein complex assembly | 59/2218 | 220/18723 | 8.55e-10 | 6.25e-08 | 59 |
GO:000038024 | Oral cavity | EOLP | alternative mRNA splicing, via spliceosome | 30/2218 | 77/18723 | 1.02e-09 | 7.13e-08 | 30 |
GO:001593121 | Oral cavity | EOLP | nucleobase-containing compound transport | 58/2218 | 222/18723 | 3.44e-09 | 2.10e-07 | 58 |
GO:005065721 | Oral cavity | EOLP | nucleic acid transport | 47/2218 | 163/18723 | 3.53e-09 | 2.12e-07 | 47 |
GO:005065821 | Oral cavity | EOLP | RNA transport | 47/2218 | 163/18723 | 3.53e-09 | 2.12e-07 | 47 |
GO:005123622 | Oral cavity | EOLP | establishment of RNA localization | 47/2218 | 166/18723 | 6.73e-09 | 3.48e-07 | 47 |
GO:002261326 | Oral cavity | EOLP | ribonucleoprotein complex biogenesis | 96/2218 | 463/18723 | 2.34e-08 | 9.81e-07 | 96 |
GO:005102821 | Oral cavity | EOLP | mRNA transport | 38/2218 | 130/18723 | 7.28e-08 | 2.61e-06 | 38 |
GO:000038124 | Oral cavity | EOLP | regulation of alternative mRNA splicing, via spliceosome | 23/2218 | 60/18723 | 1.28e-07 | 4.22e-06 | 23 |
GO:000170123 | Oral cavity | EOLP | in utero embryonic development | 72/2218 | 367/18723 | 1.02e-05 | 1.83e-04 | 72 |
GO:000640521 | Oral cavity | EOLP | RNA export from nucleus | 24/2218 | 84/18723 | 2.70e-05 | 3.95e-04 | 24 |
GO:007142621 | Oral cavity | EOLP | ribonucleoprotein complex export from nucleus | 21/2218 | 76/18723 | 1.42e-04 | 1.53e-03 | 21 |
GO:007116621 | Oral cavity | EOLP | ribonucleoprotein complex localization | 21/2218 | 77/18723 | 1.74e-04 | 1.80e-03 | 21 |
GO:000640621 | Oral cavity | EOLP | mRNA export from nucleus | 17/2218 | 59/18723 | 3.48e-04 | 3.20e-03 | 17 |
GO:007142721 | Oral cavity | EOLP | mRNA-containing ribonucleoprotein complex export from nucleus | 17/2218 | 59/18723 | 3.48e-04 | 3.20e-03 | 17 |
GO:000024521 | Oral cavity | EOLP | spliceosomal complex assembly | 20/2218 | 79/18723 | 7.07e-04 | 5.78e-03 | 20 |
GO:00400292 | Oral cavity | EOLP | regulation of gene expression, epigenetic | 24/2218 | 105/18723 | 1.07e-03 | 7.87e-03 | 24 |
GO:00090481 | Oral cavity | EOLP | dosage compensation by inactivation of X chromosome | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:00075491 | Oral cavity | EOLP | dosage compensation | 7/2218 | 18/18723 | 3.15e-03 | 1.84e-02 | 7 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDC | SNV | Missense_Mutation | rs370153946 | c.1073N>T | p.Arg358Leu | p.R358L | P19113 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A1HI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HDC | SNV | Missense_Mutation | c.611C>G | p.Ser204Cys | p.S204C | P19113 | protein_coding | tolerated(0.11) | probably_damaging(0.99) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
HDC | SNV | Missense_Mutation | rs749851294 | c.1234N>T | p.Arg412Cys | p.R412C | P19113 | protein_coding | tolerated(0.07) | probably_damaging(0.942) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HDC | SNV | Missense_Mutation | novel | c.1902N>G | p.Ile634Met | p.I634M | P19113 | protein_coding | tolerated_low_confidence(0.08) | benign(0.317) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HDC | SNV | Missense_Mutation | novel | c.1825T>G | p.Ser609Ala | p.S609A | P19113 | protein_coding | tolerated_low_confidence(0.3) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HDC | SNV | Missense_Mutation | c.1292N>A | p.Gly431Asp | p.G431D | P19113 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
HDC | SNV | Missense_Mutation | novel | c.688N>A | p.Glu230Lys | p.E230K | P19113 | protein_coding | tolerated(0.14) | benign(0.194) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
HDC | SNV | Missense_Mutation | rs777905414 | c.1748G>A | p.Arg583His | p.R583H | P19113 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HDC | SNV | Missense_Mutation | c.469G>T | p.Ala157Ser | p.A157S | P19113 | protein_coding | tolerated(0.29) | benign(0.292) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HDC | SNV | Missense_Mutation | c.487A>C | p.Lys163Gln | p.K163Q | P19113 | protein_coding | tolerated(0.08) | probably_damaging(0.94) | TCGA-CM-6680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3067 | HDC | DRUGGABLE GENOME, ENZYME | BF-DERM1 | |||
3067 | HDC | DRUGGABLE GENOME, ENZYME | inhibitor | 178101877 | ||
3067 | HDC | DRUGGABLE GENOME, ENZYME | Lixivaptan | LIXIVAPTAN | ||
3067 | HDC | DRUGGABLE GENOME, ENZYME | inhibitor | 178101826 | ||
3067 | HDC | DRUGGABLE GENOME, ENZYME | OMEPRAZOLE | OMEPRAZOLE | 8187977 | |
3067 | HDC | DRUGGABLE GENOME, ENZYME | ALPHA-FMH |
Page: 1 |